Normal responders (n=2459) | Sensitive responders (n=1366) | Highly sensitive responders (n=131) | |
Age (year), mean±SD | 55.3±15.92 | 56.5±15.58 | 56.3±17.47 |
Male, n (%) | 1486 (60.4) | 802 (58.7) | 70 (53.4) |
Race, n (%) | |||
Caucasian | 2031 (82.6) | 1122 (82.1) | 108 (82.4) |
Black | 147 (6.0) | 5 (0.4) | 0 |
Asian | 113 (4.6) | 157 (11.5) | 15 (11.5) |
Native Hawaiian/Pacific Islander | 0 | 1 (<0.1) | 0 |
Other | 164 (6.7) | 77 (5.6) | 7 (5.3) |
Weight (kg), mean±SD | 85.5±19.42 | 83.7±19.25 | 83.2±19.91 |
BMI (kg/m2), mean±SD | 28.8±5.95 | 28.3±5.45 | 28.5±6.40 |
Creatinine clearance (mL/min), mean±SD | 108.5±40.14 | 106.2±39.69 | 103.8±40.62 |
Edoxaban dose adjusted at randomisation, n (%)* | 295 (12.0) | 207 (15.2) | 17 (13.0) |
a Edoxaban patients meeting the dose reduction criteria (ie, creatinine clearance 30–50 mL/min, body weight ≤60 kg or receiving select concomitant P-gp inhibitor) had their edoxaban dose reduced to edoxaban 30 mg once daily.
All data are from baseline unless otherwise noted.
BMI, body mass index; P-gp, p-glycoprotein.